Michael J. Tucker wishes to recognize his friends and family whose love and support helped make this new edition happen, especially the indefatigable Juergen Liebermann, and of course my wonderful wife Megan and children Harry, Nick, Isabella, and Eliza, who had to suffer through all my complaints!

Juergen Liebermann gives most sincere thanks to his wife Maike and his sons and daughter Richard, Lennart Martin, Tobias Georg, Alexander Johannes, and Franziska Sophie for providing unfailing support and encouragement to bring this work to reality.
Contents

Foreword ix
Preface xi
Acknowledgments xiii
Contributors xv

1 Overview of biological vitrification
Gregory M. Fahy 1

2 Vitrification of oocytes and embryos: Finally a recognized technique, but still a source of concern and debate
Pierre Vanderzwalmen, Nicolas H. Zech, Fabien Ectors, Yannis Panagiotidis, Achillae Papatheodorou, Prapas Yannis, and Barbara Wirleitner 23

3 Intracellular concentration of cryoprotectant during vitrification and slow-freezing cryopreservation procedures

4 Importance of cooling versus warming rates in vitrification techniques
Shinsuke Seki 43

5 The movement of water and cryoprotectants in mammalian oocytes and embryos: Membrane permeability and aquaporins
Keisuke Edashige and Magosaburo Kasai 47

6 Open versus closed systems
Mark G. Larman and Pierre Vanderzwalmen 55

7 Automatic vitrification: Development of the Gavi system
Tammie K. Roy, Susanna Brandi, Cara K. Bradley, and Teija T. Peura 61

8 Vitrification at minimum volume: From basic science to clinical application
Amir Arav 69

9 Vitrification of oocytes: General considerations and the use of the Cryotec method
Masashige Kuwayama 77

10 Safety of vitrification and cryostorage and optimization of cryopreservation protocols
Lodovico Parmegiani and Marco Filicori 87

11 Physiological aspects of oocyte vitrification
Mark G. Larman and David K. Gardner 95
## CONTENTS

<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Vitrification of oocytes: Imprinting and disturbance in spindle formation and chromosome segregation</td>
<td>105</td>
</tr>
<tr>
<td></td>
<td>Tom Trapphoff</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Metabolic profile of day 3 embryos arising from vitrified oocytes</td>
<td>117</td>
</tr>
<tr>
<td></td>
<td>Damià Castelló and Francisco Domínguez</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Vitrification of human oocytes for in vitro fertilization patients</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>Laura Rienzi, Benedetta Iussig, and Filippo Maria Ubaldi</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Oocyte vitrification: Donor “egg banking”</td>
<td>129</td>
</tr>
<tr>
<td></td>
<td>Zsolt Peter Nagy, Ana Cobo, and Ching-Chien Chang</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Fertility preservation for oncology patients</td>
<td>137</td>
</tr>
<tr>
<td></td>
<td>Kara N. Goldman, Caroline McCaffrey, and Nicole Noyes</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Vitrification of human ovarian tissue</td>
<td>147</td>
</tr>
<tr>
<td></td>
<td>Mona Sheikh and Outi Hovatta</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Vitrification of cleavage-stage embryos and blastocysts and their neonatal outcomes</td>
<td>151</td>
</tr>
<tr>
<td></td>
<td>Tetsunori Mukaida and Chikahiro Oka</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Vitrification of human blastocysts: Clinical realities and neonatal outcomes</td>
<td>163</td>
</tr>
<tr>
<td></td>
<td>Juergen Liebermann</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Development and hatching of human blastocysts after vitrification and warming</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td>Joe Conaghan and Sergio Vaccari</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>Does storage of vitrified blastocysts have an impact on implantation potential and birth rate?</td>
<td>185</td>
</tr>
<tr>
<td></td>
<td>Barbara Wirleitner, Nicolas H. Zech, and Pierre Vanderzwalmen</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Ovarian tissue vitrification—Clinical realities and outcomes</td>
<td>191</td>
</tr>
<tr>
<td></td>
<td>Sherman Silver</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Vitrification of human testicular tissue, spermatogonia, and spermatozoa</td>
<td>197</td>
</tr>
<tr>
<td></td>
<td>Christine Wyns, Gael Abou-Ghannam, and Jonathan Poels</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Vitrification in pluripotent stem cell banking: Requirements and technical solutions for large-scale biobanks</td>
<td>203</td>
</tr>
<tr>
<td></td>
<td>Julia C. Neubauer, Axel F. Beier, Frank Stracke, and Heiko Zimmermann</td>
<td></td>
</tr>
<tr>
<td>25</td>
<td>Scrying the future: The ongoing transformation of reproductive medicine through vitrification</td>
<td>225</td>
</tr>
<tr>
<td></td>
<td>Kevin S. Richter, James R. Graham, and Michael J. Tucker</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Index</td>
<td>239</td>
</tr>
</tbody>
</table>
Foreword

In vitro fertilization (IVF) is, in the majority of cases, the most direct and effective solution to the current epidemic of infertility surreptitiously plaguing modern societies and wreaking havoc with their economies, while causing the grief of unwanted childlessness to ruin people's lives. Of course, IVF also poses a host of problems, but many of these can now be resolved with vitrification.

For example, most women will have more than one embryo, and before clinical use of vitrification, slow freezing of surplus embryos was problematic, yielding only inconsistent survival and pregnancy rates. Consequently, there was a strong temptation to transfer more than one or two fresh embryos to increase chances of pregnancy—thus elevating the risk of a high order of multiple pregnancies, which, as an unintended consequence, has been IVF's biggest problem. However, with the more recent introduction of vitrification technology, we are able to cryopreserve extra embryos that are not transferred, and to assure patients that this process will never damage their embryos nor necessarily lower their ultimate cumulative pregnancy rate. Indeed, clinical experience is now showing that pregnancy rates from "frozen/thawed" embryos may be even higher than those from "fresh" embryos.

The benefits of vitrification also extend beyond embryo cryopreservation, being applicable to both oocytes and ovarian tissue freezing, and including even the whole ovary. "Egg freezing" had always been somewhat of an unfulfilled dream, whereas, at least with embryo slow freezing (the norm for two decades), clinical outcomes following thawing yielded adequate survival much of the time, but still gave a distinctly lower pregnancy rate than did transfer of fresh embryos. Slow freezing of oocytes was never able to provide clinically reliable outcomes, and remained largely sidetracked as a routine procedure. The reasons are severalfold: (1) the mature oocyte is the biggest cell in the body and contains a high proportion of water, making it difficult to remove enough water during slow freezing to avoid ice crystal formation; (2) the mature oocyte, with chromosomes precariously aligned on the metaphase II spindle, is extremely sensitive to damage from ice crystal formation and may easily be disrupted; (3) the oocyte is also exquisitely vulnerable to mild chilling, which may cause significant compromise or even complete degeneration. So application of an "ultra-rapid freeze" approach with vitrification allows a consistent solution to all these problems, and has ushered in a new era of successful "egg freezing." This has kickstarted the "donor egg bank" industry, has enabled easy use of vitrification to cryostore eggs if a husband is unable to provide sperm on the day of an IVF egg retrieval, and, perhaps most importantly and of greatest media interest, has addressed the "ticking biological clock" haunting the reproductive potential of women.

The major cause of the current infertility epidemic is that women are putting off childbearing until they are older, because of better opportunities for career and education. Many women today do not consider having a baby until their mid-thirties or even later, and, by then, over 20% are infertile; by age 40, the vast majority are infertile simply because their eggs have aged significantly. However, cancer patients who have had their eggs or ovaries frozen before undergoing sterilizing chemotherapy and radiation do not have to worry about this widespread concern, because they have young eggs or ovary safely in the freezer. With vitrification, we can now achieve, in all women, that dream of safely preserving fertility in youth to protect them from the biological clock's relentless progress.

Innovating vitrification in the 1980s, and then perfecting it so that it would be more reliable in the early 2000s, was not an easy journey for its clinical pioneers, such as Rall and Fahy in the mid-1980s in the United States, and Kuwayama in Argentina and Japan in the 1990s, and up to the present. IVF clinicians were reluctant to leave the comfortable space of old ideas and the use of "slow freezing," and often ridiculed vitrification; after all, it seemed too easy, when in fact it was very difficult, simply because it has to be just exactly right to achieve success. It took much experimentation with many protocols; and having found the right one, it was most important not to tamper with it and not to deviate from the details. Cryobiology can be a very empirical science, with much painstaking trial and error (of course, based on scientifically derived postulates) over many years until you finally have the knowledge to get it right. It is not an easy procedure, with numerous points in the vitrification process of just one oocyte, and if a step is inadvertently not carried out perfectly, it spells disaster for that oocyte.

The purpose of this book, therefore, is to provide readers with all the information they will need to perfect vitrification in their own laboratories. Dr. Michael Tucker and Dr. Juergen Liebermann include every major scientist who has worked on vitrification in recent times, and describe how these individuals brought us closer to this clinical breakthrough. In addition, readers will understand the controversies and pitfalls of the process, and how to resolve and avoid such issues, allowing them to carry out a perfect job in their own IVF lab and make the dream of preserving fertility a clinical reality.

Dr. Sherman Silber
Assisted reproductive technology (ART) has been evolving for more than 30 years, and cryopreservation has become one of the keystones in such clinical infertility treatment. However, the true “explosion” in many embryologists’ minds in recognizing the true value of cryopreservation occurred with the appearance of vitrification techniques in the mid-1980s. Very gradually since that time, vitrification has established itself as “the cryopreservation technique of choice,” through consistency and predictability in terms of the quality of the cell survival following the vitrified “state of suspended animation.” Using a vitrification approach, oocyte freezing has become a reality and routine, not to mention embryo vitrification, which in turn provides outcomes comparable to those achieved with fresh transferred embryos. Furthermore, vitrification has opened the doors for new areas in the field of ART such as oocyte banking, pre-implantation diagnostics at the blastocyst stage, and notably it has helped to fuel the burgeoning adoption of elective single-embryo transfers. This final area of impact is probably the most important development, because it defines “quality of ART” in a new light—the delivery of a healthy single baby in each IVF cycle.

The success of cryopreservation in benefiting the very specialized field of ART has arisen only after much effort and is nothing short of a small miracle, given that it relies on such an intensive cooperation between science and clinical application. The development of gamete and embryo vitrification specifically represents the triumphant culmination of several decades of frustrating exploration with “slow freeze” technology. The first edition of this book, published in 2007, was subtitled: “A user manual and trouble-shooting guide.” This second edition, being published more than 7 years later, has evolved into a more comprehensive book now containing chapters reporting the successful application of vitrification from research up to the level of its use in routine clinical therapy. We as editors of this book are excited, pleased, and grateful to have chapters contributed by scientists and clinical embryologists who have been involved in the development of vitrification at the very highest level. The list of contributors demonstrates a global collaboration of professionals who have given their time, energy, and intellect to share their scientific observations and clinical experiences with the future readership of this book and beyond.

Our destiny working in the field of IVF every single day is based on strong values, and one of these is to fulfill the dreams of our patients in creating healthy families for them; vitrification plays an increasingly essential role in achieving this goal.
Acknowledgments

The editors Michael J. Tucker and Juergen Liebermann would like to thank the following individuals for their efforts in bringing this publication to fruition: Robert Peden, who as the Acquisitions Editor at CRC Press, guided us expertly and thoughtfully through the publication steps, and has been extremely helpful in keeping this publication on track throughout the vagaries of the process to provide a well-focused and timely book. All contributing authors are gratefully acknowledged for their commitment to providing current and comprehensive chapters in this area of cryobiology. Their enthusiasm and professionalism in their work is evident in their writings, and we thank them enormously for allowing us to act as coordinating editors to put this book together, on a subject that we think is both interesting and important. We are also grateful to all the River North IVF laboratory staff at the Fertility Centers of Illinois: Jill Matthews, Elissa Pelts, Becky Brohammer, Sara Sanchez, Yuri Wagner, and Ewelina Pawlowska, whose clinical skills facilitated the clinical application of routine vitrification within that laboratory; likewise, all the IVF laboratory colleagues at Shady Grove Fertility, especially Jim Graham, Josh Lim, Taer Han, Patricia Dhlakama, and Marc Portmann—to all we say a very special thank you.
Contributors

Gael Abou-Ghannam
Service de Gynécologie-Andrologie
Cliniques Universitaires Saint-Luc
Brussels, Belgium

Amir Arav
FertileSafe
Ness Ziona, Israel

Axel F. Beier
Fraunhofer Institute for Biomedical Engineering
St. Ingbert, Germany
and
Hubrecht Institute and University Medical Center Utrecht
Utrecht, the Netherlands

Cara K. Bradley
Genea Biomedx
Sydney, New South Wales, Australia

Susanna Brandi
Genea Biomedx
Sydney, New South Wales, Australia

Damià Castelló
IVI Valencia
Valencia, Spain

Ching-Chien Chang
Reproductive Biology Associates
Atlanta, Georgia

Ana Cobo
IVI-Valencia
Valencia, Spain

Joe Conaghan
Pacific Fertility Center
San Francisco, California

Delphine Connan
GIGA & FARAH Research Centers
University of Liège
Liège, Belgium

Deborah Desmet
IVF Unit
Centre Hospitalier Inter-regional Edith Cavell (CHIREC)
Braine l’Alleud, Bruxelles, Belgium

Francisco Dominguez
Fundacion Instituto Valenciano de Infertilidad (FIVI)
Instituto Universitario IVI (IUIVI) and
INCLIVA Biomedical Research Institute
Valencia, Spain

Fabien Ectors
GIGA & FARAH Transgenic Platform
University of Liège
Liège, Belgium

Keisuke Edashige
Laboratory of Animal Science
College of Agriculture
Kochi University
Nankoku, Kochi, Japan

Gregory M. Fahy
21st Century Medicine, Inc.
Fontana, California

Marco Filicori
Reproductive Medicine Unit
GynePro Medical Centers
Bologna, Italy

David K. Gardner
School of BioSciences
University of Melbourne
Melbourne, Victoria, Australia

Kara N. Goldman
New York University (NYU) Fertility Center
NYU Langone Medical Center
New York, New York

James R. Graham
Shady Grove Fertility Reproductive Science Center
Rockville, Maryland

Jacqueline Greindl
IVF Unit
Centre Hospitalier Inter-Regional Edith Cavell (CHIREC)
Braine l’Alleud, Bruxelles, Belgium

Amandine Helson
IVF Unit
Centre Hospitalier Inter-Regional Edith Cavell (CHIREC)
Braine l’Alleud, Bruxelles, Belgium

Outi Hovatta
Department of Clinical Science Intervention and Technology and Karolinska University Hospital Stockholm, Sweden

Benedetta Iussig
GENER Centres for Reproductive Medicine
Rome, Maroacita, Umbertide, Napoli, Italy

Magosaburo Kasai
Laboratory of Animal Science
College of Agriculture
Kochi University
Nankoku, Kochi, Japan

Masashige Kuwayama
Repro-Support Medical Research Centre
Shinjuku, Tokyo, Japan

Mark G. Larman
Vitrolife
Englewood, Colorado

Juergen Liebermann
Fertility Centers of Illinois
Chicago, Illinois

Caroline McCaffrey
New York University (NYU) Fertility Center
NYU Langone Medical Center
New York, New York

Tetsunori Mukaida
Hiroshima HART Clinic
Naka-ku, Hiroshima, Japan

Zsolt Peter Nagy
Reproductive Biology Associates
Atlanta, Georgia
CONTRIBUTORS

Julia C. Neubauer  
Fraunhofer Institute for Biomedical Engineering  
St. Ingbert, Germany

Nicole Noyes  
New York University (NYU) Fertility Center  
NYU Langone Medical Center  
New York, New York

Chikahiro Oka  
Tokyo HART Clinic  
Minato-ku, Tokyo, Japan

Yannis Panagiotidis  
IVF Centers Iakentro  
Thessaloniki, Greece

Achillae Papatheodorou  
IVF Centers Iakentro  
Thessaloniki, Greece

Lodovico Parmegiani  
Reproductive Medicine Unit  
GynePro Medical Centers  
Bologna, Italy

Teija T. Peura  
Genea Biomedx  
Sydney, New South Wales, Australia

Jonathan Poels  
Pôle de Gynécologie  
Institut de Recherche Expérimentale et Clinique  
Université Catholique de Louvain  
Brussels, Belgium

Kevin S. Richter  
Shady Grove Fertility Reproductive Science Center  
Rockville, Maryland

Laura Rienzi  
GENERA Centres for Reproductive Medicine  
Rome, Marostica, Umbertide, Napoli, Italy

Tammie K. Roy  
Genea Biomedx  
Sydney, New South Wales, Australia

Shinsuke Seki  
Division of Stem Cell Therapy  
Center for Stem Cell Biology and Regenerative Medicine, the Institute of Medical Science  
University of Tokyo  
Tokyo, Japan

Mona Sheikhi  
Stockholm IVF  
Stockholm, Sweden

Sherman Silber  
Infertility Center of St. Louis  
St. Lukes Hospital  
St. Louis, Missouri  
and  
Department of Obstetrics and Gynecology, Reproductive Endocrinology  
University of Amsterdam  
Amsterdam, the Netherlands

Astrid Stecher  
IVF Centers Prof. Zech  
Bregenz, Austria

Frank Stracke  
Fraunhofer Institute for Biomedical Engineering  
St. Ingbert, Germany

Tom Trapphoff  
Department of Gene Technology and Microbiology  
University of Bielefeld  
Bielefeld, Germany

Michael J. Tucker  
Shady Grove Fertility Reproductive Science Center  
Rockville, Maryland

Filippo Maria Ubaldi  
GENERA Centres for Reproductive Medicine  
Rome, Marostica, Umbertide, Napoli, Italy

Sergio Vaccari  
Pacific Fertility Center  
San Francisco, California

Pierre Vanderzwalmen  
IVF Centers Prof. Zech  
Bregenz, Austria  
and  
IVF Unit  
Centre Hospitalier Inter-Regional  
Edith Cavell (CHIREC)  
Braine l’Alleud, Bruxelles, Belgium  
and  
GIGA & FARAH Research Centers  
University of Liège  
Liège, Belgium

Sabine Vanderzwalmen  
IVF Centers Prof. Zech  
Bregenz, Austria

Christine Wyns  
Pôle de Gynécologie  
Institut de Recherche Expérimentale et Clinique  
Université Catholique de Louvain  
and  
Service de Gynécologie-Andrologie Cliniques Universitaires Saint-Luc  
Brussels, Belgium

Prapas Yannis  
IVF Centers Iakentro  
Thessaloniki, Greece

Nicolas H. Zech  
IVF Centers Prof. Zech  
Bregenz, Austria

Heiko Zimmermann  
Fraunhofer Institute for Biomedical Engineering  
St. Ingbert, Germany  
and  
Chair of Molecular and Cellular Biotechnology/Nanotechnology  
Saarland University  
Saarbrücken, Germany